戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rated by antagonist binding to the chemokine CCR5 receptor.
2 ignificantly if the target cell co-expresses CCR5 receptor.
3  the disease progression and upregulation of CCR5 receptor.
4 e binding sites for the 17b antibody and the CCR5 receptor.
5 e was selected as a targeting ligand for the CCR5 receptor.
6 l blood mononuclear cells (PBMC) lacking the CCR5 receptor.
7 nes with high levels of both the CD4 and the CCR5 receptors.
8 receptors, but not the CXCR4, CCR2, CCR4, or CCR5 receptors.
9 nds to the lower-energy conformations of the CCR5 receptor and 11 mutants.
10 R5 receptor levels and greater resistance to CCR5 receptor and fusion inhibitors compared to those wi
11 omains, increase both the ability to use the CCR5 receptor and fusion kinetics.
12                 The CTL clones expressed the CCR5 receptor and localized among HIV-infected cells exp
13  and RANTES, interfere with HIV-1 binding to CCR5 receptors and decrease the amount of virions enteri
14 erial smooth muscle cells express functional CCR5 receptors and MIP-1beta is an agonist for these cel
15 eptor, but retained the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of
16  was established before the discovery of the CCR5 receptor, and there have since been multiple report
17 genous RANTES (44AANA47-RANTES) nor the CCR1/CCR5 receptor antagonist, methionylated-RANTES, had an e
18 t LukED-dependent cell killing is blocked by CCR5 receptor antagonists, including the HIV drug maravi
19                We first used a chimeric CCR2/CCR5 receptor approach to obtain insight into the bindin
20 ors of the chemokine (C-C motif) receptor 5 (CCR5) receptor are compared for their potency as inhibit
21 ibitors of RANTES activity, Met-RANTES and a CCR5 receptor-blocking antibody.
22 oth conventional antiretroviral regimens and CCR5 receptor-blocking drugs will promote R5 virus over
23 oluble Env proteins to either the CD4 or the CCR5 receptor, but studies with a fusion-arrested Env in
24  study we show that activation of the CD4 or CCR5 receptor by R5 HIVenv causes a caspase 8-dependent
25    In the present study, donor CCR5 density (CCR5 receptors/CD4 lymphocytes) inversely correlated wit
26 n and prevents its attachment to the CD4 and CCR5 receptors, CMPD167, a small molecule that binds to
27 ing site agrees with the recent structure of CCR5 receptor cocrystallized with Maraviroc.
28 ure-activity relationships (SAR) and a human CCR5 receptor docking model using the crystal structure
29 DC) maturation, CC-chemokine production, and CCR5 receptor expression was examined using a soluble tr
30 ing CC chemokine receptor (CCR) 1, CCR3, and CCR5 receptors for RANTES chemokine was increased by Ang
31  cxcl10) chemotactic chemokines and ccr1 and ccr5 receptor genes, evaluated by reverse transcription-
32 sensitive and specific PET/CT imaging of the CCR5 receptor in an apolipoprotein E knock-out (ApoE(-/-
33 ian two-hybrid systems, we observed that the CCR5 receptor is constitutively associated with the zeta
34 eased ability to replicate in cells with low CCR5 receptor levels and greater resistance to CCR5 rece
35 CD4(+) T cells almost exclusively by CD4 and CCR5 receptor-mediated direct fusion, without requiring
36 raction of the HIV envelope with the CD4 and CCR5 receptor molecules present on the surface of target
37 ding to the virus itself and by blocking the CCR5 receptor on host cells.
38 (HIV) envelope gp120 glycoprotein to CD4 and CCR5 receptors on the plasma membrane initiates the vira
39 ients homozygous for a nonfunctional Delta32 CCR5 receptor rarely exhibit late graft loss.
40  functional "bridge" for the transmission of CCR5 receptor signaling to the cytoskeleton and nucleus,
41  PET receptor blocking studies confirmed the CCR5 receptor-specific uptake.
42 high dose' vaginal transmission model with a CCR5-receptor-using simian-human immunodeficiency virus
43 itic cells (DCs) with HIV-1 involves CD4 and CCR5 receptors, while transmission to T cells is enhance
44 truncated mutant MIP(9) was able to bind the CCR5 receptor with a K(i) of 600 pM but displayed weak a

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。